Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:CABA NASDAQ:CCCC NASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$2.05+12.0%$1.72$1.07▼$6.18$110.39M1.191.55 million shs1.92 million shsCABACabaletta Bio$3.11+2.3%$3.32$1.26▼$4.23$495.69M3.215.39 million shs5.54 million shsCCCCC4 Therapeutics$4.35+2.1%$3.57$1.39▼$4.60$471.02M2.913.22 million shs3.12 million shsPRTAProthena$9.97-0.5%$9.71$5.96▼$11.80$524.58M-0.25621,747 shs420,299 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-6.63%+4.57%+8.93%-51.72%CABACabaletta Bio0.00%+7.04%-19.58%+23.08%+93.63%CCCCC4 Therapeutics0.00%+3.15%-2.52%+81.28%+204.29%PRTAProthena0.00%+12.21%-1.57%+8.32%+64.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$2.05+12.0%$1.72$1.07▼$6.18$110.39M1.191.55 million shs1.92 million shsCABACabaletta Bio$3.11+2.3%$3.32$1.26▼$4.23$495.69M3.215.39 million shs5.54 million shsCCCCC4 Therapeutics$4.35+2.1%$3.57$1.39▼$4.60$471.02M2.913.22 million shs3.12 million shsPRTAProthena$9.97-0.5%$9.71$5.96▼$11.80$524.58M-0.25621,747 shs420,299 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics0.00%-6.63%+4.57%+8.93%-51.72%CABACabaletta Bio0.00%+7.04%-19.58%+23.08%+93.63%CCCCC4 Therapeutics0.00%+3.15%-2.52%+81.28%+204.29%PRTAProthena0.00%+12.21%-1.57%+8.32%+64.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.00Hold$5.50168.29% UpsideCABACabaletta Bio 2.57Moderate Buy$15.50398.39% UpsideCCCCC4 Therapeutics 2.57Moderate Buy$7.7578.16% UpsidePRTAProthena 2.71Moderate Buy$23.75138.21% UpsideCurrent Analyst Ratings BreakdownLatest ALDX, PRTA, CABA, and CCCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/23/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026CABACabaletta Bio Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/20/2026ALDXAldeyra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026CABACabaletta Bio Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$2.00 ➝ $4.005/14/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026PRTAProthena CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026PRTAProthena Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$19.00 ➝ $20.005/4/2026CABACabaletta Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$30.004/27/2026PRTAProthena Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CABACabaletta Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ACABACabaletta BioN/AN/AN/AN/A$1.16 per shareN/ACCCCC4 Therapeutics$35.95M13.38N/AN/A$2.65 per share1.64PRTAProthena$9.68M53.92N/AN/A$5.21 per share1.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)CABACabaletta Bio-$167.86M-$1.96N/AN/AN/AN/A-131.58%-96.46%8/6/2026 (Estimated)CCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)PRTAProthena-$244.09M-$2.82N/AN/A1.60-260.92%-43.44%-36.87%8/3/2026 (Estimated)Latest ALDX, PRTA, CABA, and CCCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CABACabaletta Bio-$0.41-$0.39+$0.02-$0.39$1.67 millionN/A5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A5/7/2026Q1 2026PRTAProthena-$0.31$0.60+$0.91$0.60$0.81 million$51.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACABACabaletta BioN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.722.72CABACabaletta BioN/A2.952.95CCCCC4 TherapeuticsN/A9.009.00PRTAProthenaN/A10.4310.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%CABACabaletta BioN/ACCCCC4 Therapeutics78.81%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics11.80%CABACabaletta Bio6.44%CCCCC4 Therapeutics5.60%PRTAProthena10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1060.32 million53.20 millionOptionableCABACabaletta Bio50163.05 million152.55 millionOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionablePRTAProthena13052.35 million46.91 millionOptionableALDX, PRTA, CABA, and CCCC HeadlinesRecent News About These CompaniesProthena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative DiseasesJune 26 at 1:50 PM | finance.yahoo.comSRPT or PRTA: Which Is the Better Value Stock Right Now?June 24, 2026 | zacks.comProthena (NASDAQ:PRTA) Major Shareholder Purchases $158,000.00 in StockJune 21, 2026 | americanbankingnews.comProthena (NASDAQ:PRTA) Major Shareholder William Scully Buys 20,000 Shares of StockJune 19, 2026 | insidertrades.comInsider Buying: Prothena (NASDAQ:PRTA) Major Shareholder Acquires 125,000 Shares of StockJune 13, 2026 | insidertrades.comProthena (NASDAQ:PRTA) Major Shareholder Acquires $465,500.00 in StockJune 6, 2026 | insidertrades.comWilliam Scully Buys 50,000 Shares of Prothena (NASDAQ:PRTA) StockJune 4, 2026 | insidertrades.comWilliam Scully Purchases 100,000 Shares of Prothena (NASDAQ:PRTA) StockMay 27, 2026 | insidertrades.comProthena Corp. PlcMay 19, 2026 | edition.cnn.comPiper Sandler Sticks to Its Buy Rating for Prothena (PRTA)May 14, 2026 | theglobeandmail.comProthena (PRTA) Gets a Hold from RBC CapitalMay 14, 2026 | theglobeandmail.comEarnings Beat: Prothena Corporation plc Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsMay 12, 2026 | finance.yahoo.comProthena: Q1 Earnings SnapshotMay 8, 2026 | wtop.comWProthena Posts Q1 Earnings as Revenues Surge on Milestone PaymentMay 8, 2026 | zacks.comProthena Reports First Quarter 2026 Financial Results and Business HighlightsMay 7, 2026 | businesswire.comProthena to Report First Quarter 2026 Financial Results on May 7April 30, 2026 | businesswire.comProthena announces Novo Nordisk obtains fast track designation from the US FDA for Coramitug (PRX004) in ATTR amyloidosis with cardiomyopathyApril 27, 2026 | msn.comProthena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyApril 27, 2026 | businesswire.comProthena Announces Leadership Team UpdatesApril 10, 2026 | businesswire.comWall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a BetMarch 26, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALDX, PRTA, CABA, and CCCC Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$2.05 +0.22 (+12.02%) Closing price 04:00 PM EasternExtended Trading$2.05 +0.00 (+0.10%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Cabaletta Bio NASDAQ:CABA$3.11 +0.07 (+2.30%) Closing price 04:00 PM EasternExtended Trading$3.14 +0.04 (+1.13%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.C4 Therapeutics NASDAQ:CCCC$4.35 +0.09 (+2.11%) Closing price 04:00 PM EasternExtended Trading$4.34 0.00 (-0.11%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Prothena NASDAQ:PRTA$9.97 -0.05 (-0.50%) Closing price 04:00 PM EasternExtended Trading$9.96 -0.02 (-0.15%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
